Skip to main content
IntoCell, Inc. logo

IntoCell, Inc. — Investor Relations & Filings

Ticker · 287840 ISIN · KR7287840003 KO Professional, scientific and technical activities
Open in API
Filings indexed 48 across all filing types
Latest filing 2022-04-08 Audit Report / Informat…
Country KR South Korea
Listing KO 287840

About IntoCell, Inc.

https://intocell.com/

IntoCell, Inc. is a biotechnology company specializing in the research and development of platform technologies for Antibody-Drug Conjugates (ADCs). The company's core focus is on creating novel biopharmaceuticals, primarily for oncology applications. IntoCell develops proprietary technologies, including its OHPAS™ linker and Payload Modification Technology (PMT™), which are designed to improve the stability, efficacy, and safety of ADC therapeutics. The company advances its own drug pipeline and also collaborates with other pharmaceutical companies through technology transfer and partnership agreements to commercialize its ADC platforms.

Recent filings

Filing Released Lang Actions
감사보고서 (2021.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'IntoCell' (주식회사 인투셀) for the fiscal year ending December 31, 2021. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a comprehensive financial report, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR). FY 2021
2022-04-08 Korean
감사보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive financial report titled '감사보고서' (Audit Report) for the company '주식회사 인투셀' (IntoCell Co., Ltd.) for the fiscal year ending December 31, 2020. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains an audit report, the document is a full set of annual financial statements prepared under K-IFRS, which is characteristic of an Annual Report (10-K equivalent in the Korean regulatory context). FY 2020
2021-04-09 Korean
감사보고서 (2019.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Intocell' (주식회사 인투셀) for the fiscal years 2018 and 2019. It includes the independent auditor's opinion, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an annual report (10-K) or a simple announcement. FY 2019
2020-03-20 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.